In yesterday’s Wall Street session, Esperion Therapeutics Inc. (NASDAQ:ESPR) shares traded at $0.88, down -10.79% from the previous session.
As of this writing, 8 analysts cover Esperion Therapeutics Inc. (NASDAQ:ESPR). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $22.00 and a low of $2.00, we find $7.00. Given the previous closing price of $0.99, this indicates a potential upside of 607.07 percent. ESPR stock price is now -15.84% away from the 50-day moving average and -58.03% away from the 200-day moving average. The market capitalization of the company currently stands at $94.58M.
There are 1 analysts who have given it a hold rating, whereas 7 have given it a buy rating. Brokers who have rated the stock have averaged $8.25 as their price target over the next twelve months.
In other news, Warren Eric, Chief Commercial Officer sold 742 shares of the company’s stock on Sep 20. The stock was sold for $924 at an average price of $1.25. Upon completion of the transaction, the Chief Commercial Officer now directly owns 68,318 shares in the company, valued at $60119.84. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 18, Chief Commercial Officer Warren Eric sold 243 shares of the business’s stock. A total of $344 was realized by selling the stock at an average price of $1.41. This leaves the insider owning 69,060 shares of the company worth $60772.8. Insiders disposed of 37,542 shares of company stock worth roughly $33036.96 over the past 1 year. A total of 0.85% of the company’s stock is owned by insiders.
During the past 12 months, Esperion Therapeutics Inc. has had a low of $0.70 and a high of $8.87. The fifty day moving average price for ESPR is $1.0504 and a two-hundred day moving average price translates $2.1063 for the stock.
The latest earnings results from Esperion Therapeutics Inc. (NASDAQ: ESPR) was released for Sep, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.46, beating analysts’ expectations of -$0.61 by 0.15. This compares to -$0.81 EPS in the same period last year. The company reported revenue of $33.97 million for the quarter, compared to $18.98 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 78.97 percent. For the current quarter, analysts expect ESPR to generate $29.58M in revenue.
Esperion Therapeutics Inc.(ESPR) Company Profile
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
